| human | Q5 |
| P496 | ORCID iD | 0000-0003-3041-1938 |
| P2038 | ResearchGate profile ID | Carl_Blomqvist |
| P1153 | Scopus author ID | 35373975300 |
| P108 | employer | Helsinki University Central Hospital | Q246315 |
| Uppsala University Hospital | Q430594 | ||
| Örebro University Hospital | Q1388689 | ||
| P734 | family name | Blomqvist | Q23656861 |
| Blomqvist | Q23656861 | ||
| Blomqvist | Q23656861 | ||
| P735 | given name | Carl | Q2529610 |
| Carl | Q2529610 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q64057560 | (Neo)adjuvant chemotherapy and interdigitated split-course hyperfractionated radiation in high risk soft tissue sarcoma - Results from a large single-institution series |
| Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
| Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
| Q33848895 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy |
| Q24600350 | 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers |
| Q36021406 | 7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium |
| Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
| Q37218535 | A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer |
| Q37486514 | A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ |
| Q33663091 | A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer |
| Q42676622 | A combined analysis of genome-wide association studies in breast cancer |
| Q57250674 | A common coding variant in CASP8 is associated with breast cancer risk |
| Q35755874 | A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer |
| Q70866349 | A cytogenetic study of malignant fibrous histiocytoma |
| Q34744122 | A genome wide meta-analysis study for identification of common variation associated with breast cancer prognosis |
| Q34613513 | A genome-wide association scan on estrogen receptor-negative breast cancer |
| Q29417036 | A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. |
| Q44761893 | A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma |
| Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
| Q36435849 | A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. |
| Q36114964 | A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer |
| Q92711687 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis |
| Q40228251 | A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer |
| Q35870483 | A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients |
| Q28384206 | A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families |
| Q52652063 | A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1). |
| Q53626719 | A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. |
| Q57305942 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer |
| Q35832325 | A web-based prognostic tool for extremity and trunk wall soft tissue sarcomas and its external validation |
| Q36113106 | ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer |
| Q91943599 | ASO Author Reflections: Registry-Based Analysis of Radiation-Associated Angiosarcoma of the Breast Provides Unbiased Insights into this Disease |
| Q33254230 | ATM variants and cancer risk in breast cancer patients from Southern Finland |
| Q28242019 | Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene |
| Q61970237 | Abstract 3274: SNP-SNP interaction analyses of NQO1 and NF-κB signaling pathway genes on breast cancer survival and treatment outcome |
| Q69536416 | Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group |
| Q43514162 | Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial |
| Q30779634 | Alcohol consumption and survival after a breast cancer diagnosis: a literature-based meta-analysis and collaborative analysis of data for 29,239 cases |
| Q70145780 | Aminoglutethimide as second line therapy in advanced breast cancer |
| Q33450749 | Aminoglutethimide for advanced prostatic cancer resistant to conventional hormonal therapy |
| Q34067081 | Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients |
| Q53985908 | Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. |
| Q35681656 | Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis |
| Q71093007 | Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer |
| Q40101346 | Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer |
| Q35218520 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy |
| Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
| Q33828680 | Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival |
| Q37684672 | Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. |
| Q37268494 | Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry |
| Q35022847 | Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies |
| Q35532898 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium |
| Q57056093 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis |
| Q51936014 | Autobiographical memories in patients treated for breast cancer. |
| Q25257890 | BACH1 Ser919Pro variant and breast cancer risk |
| Q57274795 | BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition |
| Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
| Q36643102 | Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families |
| Q41463938 | Bisphosphonate therapy in metastatic breast cancer |
| Q73879217 | Biweekly dose escalation in curative accelerated hyperfractionation for advanced head and neck cancer: a feasibility study |
| Q46115524 | Body mass index and breast cancer survival: a Mendelian randomization analysis |
| Q57396284 | Breast cancer on the Internet: the quality of Swedish breast cancer websites |
| Q46610600 | Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival |
| Q36431366 | Breast cancer risk estimation in families with history of breast cancer |
| Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
| Q35683548 | Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications |
| Q43901429 | C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer |
| Q41611265 | CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population |
| Q47236534 | CHEK2 variant I157T may be associated with increased breast cancer risk |
| Q36449203 | CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer |
| Q92005489 | Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families |
| Q33677756 | Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility |
| Q36620181 | Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors |
| Q73437638 | Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients |
| Q44853904 | Chemotherapy in Ewing's sarcoma. The Scandinavian Sarcoma Group experience |
| Q51467706 | Chronic post-treatment symptoms in patients with breast cancer operated in different surgical units. |
| Q73094960 | Clinical correlations of genetic changes by comparative genomic hybridization in Ewing sarcoma and related tumors |
| Q34573101 | Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group |
| Q73191395 | Clinical importance of genomic imbalances in synovial sarcoma evaluated by comparative genomic hybridization |
| Q73114191 | Clinical significance of genetic imbalances revealed by comparative genomic hybridization in chondrosarcomas |
| Q40405369 | Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy |
| Q43746895 | Clodronate for osteolytic metastases due to breast cancer |
| Q36116123 | Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens |
| Q46415668 | Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer |
| Q33314644 | Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk |
| Q33627208 | Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients |
| Q35891162 | Common breast cancer susceptibility loci are associated with triple-negative breast cancer |
| Q35794653 | Common germline polymorphisms associated with breast cancer-specific survival |
| Q34379032 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium |
| Q70478724 | Comparative effects of clodronate and calcitonin on bone in metastatic breast cancer: a histomorphometric study |
| Q35763987 | Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker |
| Q89671889 | Comparison between CT and MRI in detection of metastasis of the retroperitoneum in testicular germ cell tumors: a prospective trial |
| Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q71970813 | Complexity of 12q13-22 amplicon in liposarcoma: microsatellite repeat analysis |
| Q33323243 | Comprehensive analysis of NuMA variation in breast cancer |
| Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q45097069 | Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients |
| Q36615243 | Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer |
| Q54724498 | Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer. |
| Q45152218 | Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort |
| Q46778846 | Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer |
| Q54314758 | Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study. |
| Q69813514 | Cytogenetic investigations of patients on clodronate therapy for Paget's disease of bone |
| Q71005964 | Cytogenetic study of extraskeletal mesenchymal chondrosarcoma. A case report |
| Q74649716 | DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma |
| Q69862850 | Diphosphonates for osteolytic metastases |
| Q46636895 | Distribution of coronary artery stenosis after radiation for breast cancer |
| Q83223368 | Do DNA copy number changes differentiate uterine from non-uterine leiomyosarcomas and predict metastasis? |
| Q36080829 | Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? |
| Q27851413 | Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium |
| Q52131305 | Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. |
| Q54561366 | Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1. |
| Q37670843 | Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort |
| Q55110745 | E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. |
| Q72789504 | Effect of dichloromethylene diphosphonate (Cl2MDP) on immune function in breast cancer patients with bone metastases |
| Q36032149 | Effect of image compression and scaling on automated scoring of immunohistochemical stainings and segmentation of tumor epithelium |
| Q43587855 | Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area |
| Q61933712 | Effect of supervised and home exercise training on bone mineral density among breast cancer patients. A 12-month randomised controlled trial |
| Q91556882 | Effectiveness of a 12-month Exercise Intervention on Physical Activity and Quality of Life of Breast Cancer Survivors; Five-year Results of the BREX-study |
| Q48385272 | Effectiveness of a 12-month exercise program on physical performance and quality of life of breast cancer survivors |
| Q51578372 | Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer. |
| Q48401675 | Electrocardiography changes during adjuvant breast cancer therapy: incidence and risk factors |
| Q91677760 | En bloc resection of visceral aorta and right kidney due to aortic sarcoma using temporary extracorporeal bypass grafting |
| Q57250672 | Erratum: Corrigendum: A common coding variant in CASP8 is associated with breast cancer risk |
| Q62772229 | Erratum: Genome-wide scanning for linkage in Finnish breast cancer families |
| Q91452311 | Estrogen receptor beta expression correlates with proliferation in desmoid tumors |
| Q44380443 | Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment |
| Q68142781 | Evaluation of salmon calcitonin treatment in bone metastases from breast cancer--a controlled trial |
| Q39867797 | Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake |
| Q53065212 | Evaluation of the RHINO gene for breast cancer predisposition in Finnish breast cancer families. |
| Q51773668 | Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer. |
| Q57266727 | Evaluation ofRAD50 in familial breast cancer predisposition |
| Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
| Q34408752 | Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer |
| Q48084017 | Experiences of breast cancer survivors participating in a tailored exercise intervention -a qualitative study |
| Q39527705 | Experiences of clodronate treatment of multifocal eosinophilic granuloma of bone |
| Q34402838 | Expression of human chorionic gonadotropin in testicular germ cell tumors. |
| Q71937816 | Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis |
| Q37394076 | FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome |
| Q42683589 | FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population |
| Q36286955 | FEC (5-fluorouracil-epirubicin-cyclophosphamide) monthly versus FEC weekly in metastatic breast cancer. First results of a randomized trial |
| Q40639500 | FEC mobilized stem cells for high-dose therapy in breast cancer patients. SB6 9401 Study Group |
| Q37594336 | FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium |
| Q46263684 | Familial Breast Cancer in Southern Finland |
| Q57306234 | Familial breast cancer in southern Finland |
| Q53487694 | Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers. |
| Q48212258 | Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy |
| Q37307305 | Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
| Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
| Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
| Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
| Q91312432 | Functional Outcome After Lower Extremity Soft Tissue Sarcoma Treatment: A Pilot Study Based on Translated and Culturally Adapted Measures |
| Q92584270 | Functional Outcome Measurement in Patients with Lower-Extremity Soft Tissue Sarcoma: A Systematic Literature Review |
| Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
| Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
| Q71598960 | Gains and losses of DNA sequences in liposarcomas evaluated by comparative genomic hybridization |
| Q38627916 | Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication |
| Q33589487 | Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes |
| Q37739048 | Genetic modifiers of CHEK2*1100delC-associated breast cancer risk |
| Q35925620 | Genetic predisposition to ductal carcinoma in situ of the breast |
| Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
| Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
| Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
| Q35029543 | Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer |
| Q28388497 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types |
| Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q63681757 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q29417100 | Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer |
| Q95329367 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses |
| Q64040390 | Genome-wide association study of germline variants and breast cancer-specific mortality |
| Q57274804 | Genome-wide scanning for linkage in Finnish breast cancer families |
| Q34173446 | Genome-wide search for breast cancer linkage in large Icelandic non-BRCA1/2 families |
| Q24595882 | Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics |
| Q33901605 | Germ-line variation at a functional p53 binding site increases susceptibility to breast cancer development |
| Q45733546 | Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women |
| Q34158129 | Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome |
| Q58751760 | Ghrelin expression is associated with a favorable outcome in male breast cancer |
| Q57306210 | Glycodelin expression associates with differential tumour phenotype and outcome in sporadic and familial non-BRCA1/2 breast cancer patients |
| Q36135359 | Growth rate of lung metastases and S-phase fraction as determined by flow cytometry from the primary tumour in 25 patients with bone or soft-tissue sarcomas |
| Q30932448 | HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review |
| Q36115998 | Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer |
| Q47762473 | Health-related Quality of Life in Breast Cancer Patients after Adjuvant Treatments |
| Q89947338 | Health-related Quality of Life of Breast Cancer Survivors Attending an Exercise Intervention Study: A Five-year Follow-up |
| Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
| Q33330850 | Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics |
| Q36547888 | Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers |
| Q89022860 | High cyclin A expression, but not Ki67, is associated with early recurrence in desmoid tumors |
| Q37160662 | High cyclin B1 expression is associated with poor survival in breast cancer |
| Q33867326 | High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers |
| Q51283625 | High frequency of osteonecrosis of the jaw among denosumab-treated prostate cancer patients. |
| Q72189264 | Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer |
| Q24796660 | Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families |
| Q50792617 | Hyperglycosylated human chorionic gonadotropin in serum of testicular cancer patients. |
| Q41664729 | INPP4B and RAD50 have an interactive effect on survival after breast cancer |
| Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q35051431 | Identification of genetic markers with synergistic survival effect in cancer |
| Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
| Q28943279 | Identification of inherited genetic variations influencing prognosis in early-onset breast cancer |
| Q36014067 | Identification of novel genetic markers of breast cancer survival |
| Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
| Q36912269 | Impact of the smallest surgical margin on local control in soft tissue sarcoma |
| Q37597148 | Improved prognosis in soft-tissue sarcoma of extremity and trunk wall |
| Q114184688 | Incorporating progesterone receptor expression into the PREDICT breast prognostic model |
| Q53195496 | Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer. |
| Q70590750 | Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration |
| Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
| Q88804556 | Inter-observer variation in delineating the coronary arteries as organs at risk |
| Q92924767 | Kaposi sarcoma in Southern Finland (2006-2018) |
| Q57306217 | Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? |
| Q57191573 | Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair |
| Q28267893 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair |
| Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
| Q36620540 | Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF |
| Q51647923 | Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. |
| Q51643092 | Long-term effects of dichloromethylene diphosphonate in patients with osteolytic bone metastases and coincident primary hyperparathyroidism |
| Q43614359 | Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy |
| Q43807555 | Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment |
| Q73686881 | Long-term prognostic impact of immunohistochemical estrogen receptor determinations compared with biochemical receptor determination in primary breast cancer |
| Q92331163 | Long-term results of surgical resection of lung metastases from soft tissue sarcoma: A single center experience |
| Q92857529 | Long-term risk of ischemic heart disease after adjuvant radiotherapy in breast cancer: results from a large population-based cohort |
| Q33758934 | Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study |
| Q35119701 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium |
| Q39319847 | Marginal miss or radioresistance? The pattern of local recurrence after operation and 3D planned radiation treatment in soft tissue sarcoma of the extremities and the limb girdles; an analysis based on image fusion. |
| Q36134836 | Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma |
| Q33295438 | Mast cells and eosinophils in invasive breast carcinoma |
| Q35977152 | Measurement of growth rate of lung metastases in 21 patients with bone or soft-tissue sarcoma |
| Q49252742 | Meta-analysis of three genome-wide association studies identifies two loci that predict survival and treatment outcome in breast cancer. |
| Q92701699 | Metaplastic carcinoma of the breast: Prognosis and response to systemic treatment in metastatic disease |
| Q34079217 | MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer |
| Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
| Q84520864 | Microvascular reconstructions after extensive soft tissue sarcoma resections in the upper limb |
| Q34123806 | Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls |
| Q34493998 | Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study |
| Q33628755 | Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility |
| Q42174486 | Multicellular tumour spheroid as a model for evaluation of [18F]FDG as biomarker for breast cancer treatment monitoring |
| Q57232775 | Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q46567991 | NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer |
| Q57306207 | NQO1 expression correlates inversely with NFκB activation in human breast cancer |
| Q37356243 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q37308596 | No evidence that GATA3 rs570613 SNP modifies breast cancer risk |
| Q57306224 | No germline FH mutations in familial breast cancer patients |
| Q35098350 | Nuclear osteopontin-c is a prognostic breast cancer marker |
| Q46022083 | Obesity and physical inactivity are related to impaired physical health of breast cancer survivors. |
| Q56529212 | Omitting radiotherapy in women ≥ 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe |
| Q72312895 | Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma |
| Q47904430 | Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer |
| Q73835348 | Overrepresentation of 1q21-23 and 12q13-21 in lipoma-like liposarcomas but not in benign lipomas: a comparative genomic hybridization study |
| Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
| Q47143943 | PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. |
| Q36184231 | PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. |
| Q33345859 | Paclitaxel-ifosfamide for anthracycline-resistant advanced breast cancer. |
| Q34289136 | Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche |
| Q112572520 | Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes |
| Q37307937 | Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium |
| Q36873786 | Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium |
| Q43979870 | Physical performance, toxicity, and quality of life as assessed by the physician and the patient |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q37131918 | Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families |
| Q36071595 | Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy |
| Q57274822 | Population-Based Study of BRCA1 and BRCA2 Mutations in 1035 Unselected Finnish Breast Cancer Patients |
| Q33784165 | Post-mastectomy radiotherapy in pT3N0M0 breast cancer: is it needed? |
| Q92055460 | Prediction and clinical utility of a contralateral breast cancer risk model |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q41463944 | Predictive factors for response to cytotoxic treatment in advanced breast cancer: a review |
| Q36431192 | Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer |
| Q46523457 | Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer |
| Q74216114 | Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer |
| Q73603333 | Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients |
| Q33701104 | Prognostic factors in soft tissue sarcoma. A review and the Scandinavian Sarcoma Group experience. |
| Q53241753 | Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. |
| Q46868740 | Prognostic role of HuR in hereditary breast cancer |
| Q44490957 | Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer |
| Q71096919 | Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study |
| Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
| Q90242034 | Publisher Correction: Shared heritability and functional enrichment across six solid cancers |
| Q43845683 | Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study |
| Q48782678 | Quality of life and physical performance and activity of breast cancer patients after adjuvant treatments. |
| Q48717671 | Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group. |
| Q48084016 | Quality of life of recently treated patients with breast cancer |
| Q35502165 | RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families |
| Q36009422 | RAD51B in Familial Breast Cancer |
| Q57306209 | RAD51C is a susceptibility gene for ovarian cancer |
| Q57274817 | RESPONSE: Re: Population-Based Study of BRCA1 and BRCA2 Mutations in 1035 Unselected Finnish Breast Cancer Patients |
| Q53733512 | Radiation dose distribution in coronary arteries in breast cancer radiotherapy. |
| Q37123499 | Radiation to supraclavicular and internal mammary lymph nodes in breast cancer increases the risk of stroke |
| Q90462911 | Radiation-associated sarcoma after breast cancer in a nationwide population: Increasing risk of angiosarcoma |
| Q50976770 | Radiotherapy in desmoid tumors : Treatment response, local control, and analysis of local failures. |
| Q39882597 | Recruitment of breast cancer survivors into a 12-month supervised exercise intervention is feasible |
| Q36421638 | Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization |
| Q92710828 | Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients |
| Q43821574 | Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma |
| Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
| Q24810584 | Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families |
| Q36614316 | Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides |
| Q92233724 | Reply-Letter to the editor |
| Q45951126 | Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. |
| Q58281581 | Results of Treatment in Testicular Nonseminoma |
| Q57306230 | Risk of cancer in BRCA1 and BRCA2 mutation-positive and -negative breast cancer families (Finland) |
| Q37300024 | Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. |
| Q88580715 | Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ |
| Q36545934 | SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival |
| Q72082642 | Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer |
| Q57754538 | Screening of HELQ in breast and ovarian cancer families |
| Q43780256 | Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer |
| Q61118451 | Shared heritability and functional enrichment across six solid cancers |
| Q64004349 | Shared heritability and functional enrichment across six solid cancers |
| Q45065765 | Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure |
| Q44910541 | Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel |
| Q73190727 | Soft tissue sarcomas of the lower extremity: surgical treatment and outcome |
| Q33593016 | Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies |
| Q52972843 | Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. |
| Q38492869 | Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland |
| Q33566957 | TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer |
| Q52072195 | Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. |
| Q34489605 | Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status |
| Q36695459 | Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids |
| Q44956804 | Ten years' experience in patients with osteogenic sarcoma in Finland |
| Q45007476 | Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer |
| Q45151602 | Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients |
| Q36115781 | Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence |
| Q92577780 | The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report |
| Q46914764 | The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer |
| Q91178389 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer |
| Q35781316 | The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients |
| Q53978964 | The Scandinavian Sarcoma Group--background, organization and the SSG Register--the first 25 years. |
| Q53544991 | The Scandinavian Sarcoma Group. Background, organization and the Central Register--the first 20 years. |
| Q46041916 | The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype |
| Q35994659 | The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial |
| Q24652535 | The combined status of ATM and p53 link tumor development with therapeutic response |
| Q28362960 | The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer |
| Q86863198 | The effect of ovarian dysfunction on bone mineral density in breast cancer patients 10 years after adjuvant chemotherapy |
| Q84797821 | The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer |
| Q71145009 | The importance of a multidisciplinary group in the treatment of soft tissue sarcomas |
| Q73347720 | The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group experience |
| Q43918657 | The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. |
| Q72165346 | The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen. Eight year follow-up results of a randomized trial |
| Q35660389 | The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study |
| Q64123546 | The relationship between radiation doses to coronary arteries and location of coronary stenosis requiring intervention in breast cancer survivors |
| Q68202385 | The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy, and biochemical markers of bone metabolism |
| Q36142060 | The role of genetic breast cancer susceptibility variants as prognostic factors |
| Q46283304 | Three-year oral clodronate treatment does not impair mineralization of newly formed bone--a histomorphometric study |
| Q43724371 | Timing of quality of life (QoL) assessments as a source of error in oncological trials |
| Q83465151 | Trabectedin in the treatment of metastatic soft-tissue sarcoma: cost-effectiveness and cost-utility are yet to be proved |
| Q89961489 | Transcriptome-wide association study of breast cancer risk by estrogen-receptor status |
| Q91481267 | Treatment and Prognosis of Radiation-Associated Breast Angiosarcoma in a Nationwide Population |
| Q70042371 | Treatment of skeletal disease in breast cancer: a controlled clodronate trial |
| Q51551032 | Treatment-related factors predisposing to chronic pain in patients with breast cancer--a multivariate approach. |
| Q36644638 | Tumour microvessel density as predictor of chemotherapy response in breast cancer patients |
| Q92994868 | Two truncating variants in FANCC and breast cancer risk |
| Q36134368 | Type I and type III collagen metabolites in adult osteosarcoma patients |
| Q42372100 | Type III collagen metabolism in soft tissue sarcomas |
| Q57306205 | Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer |
| Q35889659 | Variants on the promoter region of PTEN affect breast cancer progression and patient survival |
| Q71127422 | Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study |
| Q44537437 | Vinorelbine, epirubicin and fluorouracil as first-line therapy in metastatic breast cancer--a phase II trial |
| Q43478535 | Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial |
| Q68045020 | Weekly low-dose doxorubicin as second line therapy in advanced breast cancer |
| Q70060565 | Weekly low-dose doxorubicin with or without high-dose medroxyprogesterone acetate as secondary treatment in metastatic breast cancer--a randomized trial |
| Q72133687 | [Adjuvant chemotherapy of breast cancer] |
| Q74002819 | [Chronic pain and other symptoms following treatment of breast cancer] |
| Q57140365 | [Ki-67 and cyclin A--prognostic factors in breast cancer. Time to introduce proliferation markers in clinical routine] |
| Q55670947 | p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition |
| Q37414133 | rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk |
Search more.